Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00605020
Other study ID # NN304-1558
Secondary ID
Status Completed
Phase Phase 3
First received January 17, 2008
Last updated June 26, 2017
Start date December 2, 2003
Est. completion date March 3, 2005

Study information

Verified date June 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is conducted in Europe.

The aim of this trial is to investigate the efficacy and safety of an intensified treatment regimen with preprandial insulin aspart and insulin detemir once or twice daily to a more convenient regimen with biphasic insulin aspart 30 twice daily on blood glucose control in subjects with type 2 diabetes.


Recruitment information / eligibility

Status Completed
Enrollment 719
Est. completion date March 3, 2005
Est. primary completion date March 3, 2005
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetes

- Duration of type 2 diabetes for at least 6 months since diagnosis

- Current treatment with one or two oral antidiabetic drugs for at least 3 months or with one or two oral antidiabetic drugs, given for at least 3 months in combination with intermediate or long-acting insulin/insulin analogue once daily

- BMI below 40 kg/m2

- HbA1c between 7-12%

- Able and willing to perform self-monitoring of capillary blood glucose

Exclusion Criteria:

- Current antidiabetic treatment with combination of three or more oral antidiabetic drugs

- Previous treatment with short-acting human insulin, short-acting insulin analogue or biphasic insulin/insulin analogue within the last 6 months (7 days or less within the last 6 months is allowed)

- Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator

- Known or suspected allergy to trial product or related products

- Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures

- Receipt of any investigational drug within 4 weeks prior to this trial

- Previous participation in this trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
insulin detemir

insulin aspart

Device:
biphasic insulin aspart


Locations

Country Name City State
Austria Novo Nordisk Investigational Site Graz
Austria Novo Nordisk Investigational Site Linz
Austria Novo Nordisk Investigational Site Wien
Austria Novo Nordisk Investigational Site Wien
Austria Novo Nordisk Investigational Site Wien
Germany Novo Nordisk Investigational Site Alsdorf
Germany Novo Nordisk Investigational Site Altenburg
Germany Novo Nordisk Investigational Site Altenkirchen
Germany Novo Nordisk Investigational Site Altenstadt
Germany Novo Nordisk Investigational Site Aschaffenburg
Germany Novo Nordisk Investigational Site Augsburg
Germany Novo Nordisk Investigational Site Bad Harzburg
Germany Novo Nordisk Investigational Site Bad Heilbrunn
Germany Novo Nordisk Investigational Site Bad Kreuznach
Germany Novo Nordisk Investigational Site Bad Lauterberg
Germany Novo Nordisk Investigational Site Bad Lippspringe
Germany Novo Nordisk Investigational Site Bad Mergentheim
Germany Novo Nordisk Investigational Site Bad Neuenahr-Ahrweiler
Germany Novo Nordisk Investigational Site Bad Oldesloe
Germany Novo Nordisk Investigational Site Bad Staffelstein
Germany Novo Nordisk Investigational Site Bensheim
Germany Novo Nordisk Investigational Site Berlin
Germany Novo Nordisk Investigational Site Berlin
Germany Novo Nordisk Investigational Site Berlin
Germany Novo Nordisk Investigational Site Berlin
Germany Novo Nordisk Investigational Site Berlin
Germany Novo Nordisk Investigational Site Berlin
Germany Novo Nordisk Investigational Site Bochum
Germany Novo Nordisk Investigational Site Damme
Germany Novo Nordisk Investigational Site Diez
Germany Novo Nordisk Investigational Site Dinslaken
Germany Novo Nordisk Investigational Site Dormagen
Germany Novo Nordisk Investigational Site Dortmund
Germany Novo Nordisk Investigational Site Dortmund
Germany Novo Nordisk Investigational Site Dresden
Germany Novo Nordisk Investigational Site Dresden
Germany Novo Nordisk Investigational Site Duisburg
Germany Novo Nordisk Investigational Site Duisburg
Germany Novo Nordisk Investigational Site Emmerich
Germany Novo Nordisk Investigational Site Essen
Germany Novo Nordisk Investigational Site Essen
Germany Novo Nordisk Investigational Site Flensburg
Germany Novo Nordisk Investigational Site Flörsheim
Germany Novo Nordisk Investigational Site Forchheim
Germany Novo Nordisk Investigational Site Frankfurt
Germany Novo Nordisk Investigational Site Frankfurt
Germany Novo Nordisk Investigational Site Frankfurt
Germany Novo Nordisk Investigational Site Frankfurt
Germany Novo Nordisk Investigational Site Freiburg
Germany Novo Nordisk Investigational Site Freital
Germany Novo Nordisk Investigational Site Gebhardshain
Germany Novo Nordisk Investigational Site Genthin
Germany Novo Nordisk Investigational Site Georgsmarienhütte
Germany Novo Nordisk Investigational Site Giessen
Germany Novo Nordisk Investigational Site Gotha
Germany Novo Nordisk Investigational Site Halle
Germany Novo Nordisk Investigational Site Hamburg
Germany Novo Nordisk Investigational Site Hamburg
Germany Novo Nordisk Investigational Site Hamburg
Germany Novo Nordisk Investigational Site Hamburg
Germany Novo Nordisk Investigational Site Hameln
Germany Novo Nordisk Investigational Site Hannover
Germany Novo Nordisk Investigational Site Herne
Germany Novo Nordisk Investigational Site Herrenberg
Germany Novo Nordisk Investigational Site Hildesheim
Germany Novo Nordisk Investigational Site Hohenmölsen
Germany Novo Nordisk Investigational Site Hünxe
Germany Novo Nordisk Investigational Site Idar-Oberstein
Germany Novo Nordisk Investigational Site Jena
Germany Novo Nordisk Investigational Site Kaiserslautern
Germany Novo Nordisk Investigational Site Karlsruhe
Germany Novo Nordisk Investigational Site Krummennaab
Germany Novo Nordisk Investigational Site Künzing
Germany Novo Nordisk Investigational Site Landau
Germany Novo Nordisk Investigational Site Langen
Germany Novo Nordisk Investigational Site Lindenfels
Germany Novo Nordisk Investigational Site Lübeck
Germany Novo Nordisk Investigational Site Mainz
Germany Novo Nordisk Investigational Site Marburg
Germany Novo Nordisk Investigational Site Marktheidenfeld
Germany Novo Nordisk Investigational Site Meppen
Germany Novo Nordisk Investigational Site Mühlheim
Germany Novo Nordisk Investigational Site München
Germany Novo Nordisk Investigational Site Neumünster
Germany Novo Nordisk Investigational Site Neuwied
Germany Novo Nordisk Investigational Site Nittenau
Germany Novo Nordisk Investigational Site Northeim
Germany Novo Nordisk Investigational Site Oberhausen
Germany Novo Nordisk Investigational Site Oberndorf
Germany Novo Nordisk Investigational Site Oberursel
Germany Novo Nordisk Investigational Site Offenbach
Germany Novo Nordisk Investigational Site Osnabrück
Germany Novo Nordisk Investigational Site Pforzheim
Germany Novo Nordisk Investigational Site Pirna
Germany Novo Nordisk Investigational Site Regensburg
Germany Novo Nordisk Investigational Site Rehlingen-Siersburg
Germany Novo Nordisk Investigational Site Saaldorf-Surheim
Germany Novo Nordisk Investigational Site Saarbrücken
Germany Novo Nordisk Investigational Site Sangerhausen
Germany Novo Nordisk Investigational Site Schaafheim
Germany Novo Nordisk Investigational Site Schkeuditz
Germany Novo Nordisk Investigational Site Schlüchtern
Germany Novo Nordisk Investigational Site Schwerin
Germany Novo Nordisk Investigational Site Schwerin
Germany Novo Nordisk Investigational Site Schwerte
Germany Novo Nordisk Investigational Site Siegen
Germany Novo Nordisk Investigational Site Simmern
Germany Novo Nordisk Investigational Site Sinsheim
Germany Novo Nordisk Investigational Site Sögel
Germany Novo Nordisk Investigational Site Speyer
Germany Novo Nordisk Investigational Site St. Ingbert
Germany Novo Nordisk Investigational Site Stuttgart
Germany Novo Nordisk Investigational Site Sulzbach-Rosenberg
Germany Novo Nordisk Investigational Site Trier
Germany Novo Nordisk Investigational Site Tübingen
Germany Novo Nordisk Investigational Site Völklingen
Germany Novo Nordisk Investigational Site Wallerfing
Germany Novo Nordisk Investigational Site Wangen
Germany Novo Nordisk Investigational Site Warburg
Germany Novo Nordisk Investigational Site Wiesbaden
Germany Novo Nordisk Investigational Site Wilhelmshaven
Germany Novo Nordisk Investigational Site Würzburg
Switzerland Novo Nordisk Investigational Site Basel-Bruderholz
Switzerland Novo Nordisk Investigational Site Genève 14
Switzerland Novo Nordisk Investigational Site Lugano
Switzerland Novo Nordisk Investigational Site St. Gallen
Switzerland Novo Nordisk Investigational Site Zürich

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Austria,  Germany,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary HbA1c after 6 months of treatment
Secondary Incidence of hypoglycaemic episodes
Secondary Adverse events
Secondary Difference of HbA1c change between the two groups after 13 weeks of treatment
Secondary Fasting plasma glucose of treatment after 13 and 26 weeks
Secondary Change in weight
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2